Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
Antiviral compounds
US9511059B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9511059-B2 |
| Application number | US-201514827762-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 17, 2015 |
| Priority date | Jan 23, 2013 |
| Publication date | Dec 6, 2016 |
| Grant date | Dec 6, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound selected from the group consisting of: N5-(3-Fluoro-4-phenylsulfanyl-5-trifluoromethyl-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3-(3-Chloro-4-phenylamino-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3-(3-Chloro-4-phenoxy-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3-(3,5-Dichloro-4-phenylsulfanyl-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3-(4-Benzenesulfinyl-3,5-dichloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3-(4-Benzenesulfinyl-3,5-dichloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3-[3,5-Dichloro-4-(4-trifluoromethyl-phenylsulfanyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N3-[3,5-Dichloro-4-(4-trifluoromethyl-benzenesulfinyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N3-[3,5-Dichloro-4-(4-trifluoromethyl-benzenesulfinyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3,5-Dichloro-4-(2-trifluoromethyl-phenylsulfanyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3,5-Dichloro-4-(3-trifluoromethyl-benzenesulfinyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; 4-[4-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2,6-dichloro-phenylsulfanyl]-benzonitrile; 4-[4-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2,6-dichloro-benzenesulfinyl]-benzonitrile; 4-[4-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2,6-dichloro-benzenesulfonyl]-benzonitrile; 4-[4-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2-chloro-6-trifluoromethyl-phenylsulfanyl]-benzoic acid methyl ester; N 3 -[3,5-Dichloro-4-(4-methoxy-phenylsulfanyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3-Chloro-4-(4-methoxy-phenylsulfanyl)-5-trifluoromethyl-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3,5-Dichloro-4-(4-methoxy-benzenesulfonyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3,5-Dichloro-4-(4-methanesulfonyl-phenoxy)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3-Chloro-4-(4-methanesulfonyl-phenoxy)-5-trifluoromethyl-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -(3-Chloro-4-phenylsulfanyl-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -(4-Benzenesulfonyl-3-chloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -(3-Chloro-4-phenylsulfanyl)-N 3 -methyl-1H-[1,2,4]triazole-3,5-diamine; N 3 -(3-Chloro-5-phenoxy-phenyl)-1H-[1,2,4]triazole-3,5-diamine; and N 3 -[3,5-Dichloro-4-(pyridin-2-yloxy)-phenyl]-1H-[1,2,4]triazole-3,5-diamine.
Assignees
Inventors
Classifications
for RNA viruses · CPC title
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Nitrogen atoms · CPC title
- A61K31/4439Primary
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9511059B2 cover?
- The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4439. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).